Mechanism of action
Saquinavir belongs to HIV protease inhibitors. The drug blocks a specific viral enzyme, disrupting the maturation of viral particles. Membrane transporters, particularly P-glycoprotein (a protein from the family of ATP-dependent ABC transporters), play a crucial role in saquinavir pharmacokinetics. P-glycoprotein is localized on the apical membrane of the placental trophoblast and plays a protective role by pumping lipophilic compounds (including HIV protease inhibitors) back into the maternal bloodstream, preventing them from reaching the fetus.
Pharmacological effects
Being a P-glycoprotein substrate, saquinavir undergoes active transmembrane transport. When co-administered with P-glycoprotein inhibitors (such as quinidine Chinidinum, lidocaine Lidocainum, verapamil Verapamilum), the placental protective barrier weakens, which facilitates drug penetration across histohematic barriers and increases toxic effects on the fetus. Saquinavir pharmacokinetics is also affected by the CYP3A4 isoenzyme in the liver and intestinal wall, the activity of which can be modulated to increase drug bioavailability.
Indications
The drug is prescribed as part of combination antiretroviral therapy for HIV infection. In clinical practice, protease inhibitors require frequent administration (3 times a day or more), but to optimize the dosage regimen and reduce the frequency of administration, pharmacological boosters (ritonavir boosting effect) are used, which inhibit CYP3A4 and reduce presystemic elimination.
Side effects and contraindications
The main safety aspect when prescribing saquinavir is its drug interactions. Co-administration with P-glycoprotein inhibitors blocks the protective efflux in the placenta, increasing the risk of fetal toxicity. Sex and genetic factors of variability are also taken into account: P-glycoprotein gene expression in men is more than 2 times higher than in women, which affects individual pharmacokinetics.
Prescription details
Saquinavir is available in 0.2 g capsules. The standard dosage for oral administration is 0.6 g. Most protease inhibitors are better absorbed when taken with food. To overcome rapid metabolism, saquinavir is often combined with ritonavir, which acts not so much as an antiviral agent, but as a pharmacokinetic enhancer that suppresses presystemic elimination.
Briefly: answers to topical questions
What specific side effects does saquinavir cause?
With prolonged use, saquinavir causes specific side effects affecting metabolism, kidneys, and liver. These include metabolic disorders such as elevated atherogenic lipoproteins and hyperglycemia, which creates a risk of developing diabetes mellitus. Alterations in adipose tissue distribution presenting as lipodystrophy, nephrolithiasis, and hepatotoxicity are also observed.
- Lipodystrophy () — Adipose tissue distribution
- Nephrolithiasis () — Kidney stone formation
- Hepatotoxicity () — Impaired liver function
"Saquinavir is the very first among proteases" (introduced in the mid-1990s as the pioneer of the HIV protease inhibitor group).
Class and exam questions
What generation or group does saquinavir belong to?
Saquinavir is the first representative of the HIV protease inhibitor group, introduced into clinical practice in the mid-1990s.
What is the standard dosage form and dosage of the drug according to the reference book?
The drug is available in 0.2 g capsules, taken orally at a dose of 0.6 g.
What is the protective role of placental P-glycoprotein during saquinavir administration?
P-glycoprotein on the apical membrane of the trophoblast performs unidirectional efflux of protease inhibitors into maternal blood, protecting the fetus from toxic effects.
What mechanism underlies the "booster" effect of ritonavir in combination with protease inhibitors?
Ritonavir inhibits the CYP3A4 isoenzyme in the liver and intestinal wall, which reduces presystemic elimination and increases the bioavailability of the main drug.
What else to study on this topic
- Structure and function of placental ATP-dependent ABC transporters
- Pharmacokinetic interaction of HIV protease inhibitors and CYP3A4 substrates
- Sex and genetic differences in P-glycoprotein expression
- The role of ritonavir as a pharmacokinetic enhancer (booster)
- Effect of food intake on the absorption of protease inhibitors
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Saquinavir" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.